Here are four insights:
1. The preclinical study revealed the growth factor successfully encourages bone formation in a phylogenetically advanced spine model.
2. The rhNELL-1 growth factor did not cause inflammation and was well tolerated.
3. Bone Biologics plans to launch a pivotal animal study in mid-2018.
4. The company’s rhNELL-1 program is set for human trials in 2019.
More articles on biologics:
HSS’ Dr. Christopher Mendias earns $800k grant for stem cell research — 5 notes
Denver Bronco Derek Wolfe to undergo stem cell treatment after diagnosis from Dr. Robert Watkins — 3 things to know
How do muscle stem cells react to injury and aging? 6 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.